The doctors consider mSMART classification to look at high-, intermediate-, and standard-risk myeloma. They discuss, with the increasing depth of response in myeloma with the newer drugs, how doctors should evaluate the use of these drugs with the higher-risk disease groups. 

IMWG Myeloma Experts debate the latest trends in treatment
June 9, 2016
Copenhagen, Denmark

Previous Post
IMWG Conference Series - Copenhagen 2016: Are you proactive regarding your patients’ comorbidities?
Next Post
IMWG Conference Series - Copenhagen 2016: What is the impact of the new diagnostic criteria?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.